Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Jun 16, 2023
Deals
Surface accepts buyout; deal helps Coherus build innovative pipeline
Nine-year-old immuno-oncology company’s value had dwindled since deprioritizing CD47 program, entering GSK deal
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Aug 5, 2022
Finance
Aug. 4 Quick Takes: Forbion, Sofinnova lead F2G’s $70M financing
Plus newco emerges from Daley lab and updates Lilly, Pfizer, Regeneron, Arucs-Gilead, Travere, BioCryst and more
BioCentury | Jun 17, 2022
Product Development
First-in-human cancer trials delivering translational innovation
New targets displaced validated mechanisms in first-in-human abstracts at ASCO 2022
BioCentury | May 28, 2022
Product Development
May 27 ASCO Quick Takes: SpringWorks falls on weakness of combo data
Plus abstracts from Adicet, IMAB, PMV and a tumble for Iovance
BioCentury | Apr 16, 2022
Product Development
Where Gilead is looking next in oncology
The company aims to sift through combinations quickly via platform trials, and is outlining its next priority target and technology spaces in cancer
BioCentury | Nov 24, 2021
Discovery & Translation
New mechanisms and modalities emerge for TIGIT
2021 ASH and SITC abstracts are low on data, high on innovation
Items per page:
1 - 10 of 46